Brought to you by 
Monogram Biosciences, Pfizer collaborate on HIV assay
May 2006
Executive Summary
Building on a 2002 partnership in HIV, Monogram Biosciences and Pfizer have entered a new three-year deal to collaborate on the development of Monogram's co-receptor tropism assay, which is now being used in clinical trials for HIV/AIDS indications of Pfizer's Maraviroc, a Phase III CCR5-antagonist compound.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Monogram Biosciences, Pfizer collaborate on HIV assay
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice